
Paradigm’s Kurt Mussina discusses why scale should drive operational efficiency, not consolidation into single-site studies.
Antimicrobial resistance remains a health and financial danger worldwide. Vaccines can both help reduce disease and combat antimicrobial resistance. Despite advancements, making antibacterial vaccines remains challenging.






